The quality of care delivered by health plans that report performance data to the National Committee for Quality Assurance improved markedly in 2003, according to the organization's annual industry report, though NCQA officials are quick to add that they're worried about what's going on at those plans that do not participate in accreditation.

"The performance improvements recorded last year among the 563 health plans that reported results were among the largest ever recorded," notes the State of Health Care Quality 2004. "...On several key measures, average health plan performance improved by 4 percentage points or more."

However, the report also examines data collected by some of the health plans that refuse to be indentified to the public. About 75 percent of enrollees belong to plans that do not report quality information publicly. Those plans "nonpublic reporters " lag in nearly every quality category. But, as NCQA spokesman Brian Schilling told us, "At least they're measuring something." PPOs and consumer-directed health plans do not participate in HEDIS performance measurement at all, even anonymously.

As the report states: "At a time when the national trend in health insurance is to move away from the tight networks of health maintenance organizations toward the broader access of preferred provider organizations and the Web-powered promise of 'consumer-directed' health plans (CDHP), there is also a danger that some of the gains of the past decade — a result of a focus on plan-initiated care management and preventive care — will be lost."

Nonpublic reporters don't score as high

The numbers reflect the percentage of people enrolled in those plans that get the right care (e.g., 88 percent of people enrolled in publicly reporting plans who have diabetes will get a lipid profile test at an appropriate interval).


Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.